187 related articles for article (PubMed ID: 33206598)
1. Re: Maha Hussain, Joaquin Mateo, Karim Fizazi, et al. Survival with Olaparib in Metastatic Castration-resistant Prostate Cancer. N Engl J Med. In press. https://doi.org/10.1056/NEJMoa2022485.
Rizzo A; Mollica V; Massari F
Eur Urol Oncol; 2020 Dec; 3(6):806. PubMed ID: 33206598
[No Abstract] [Full Text] [Related]
2. Reply to Johann S. de Bono, Maha Hussain, and Jinyu Kang's Letter to the Editor re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024.
Stopsack KH
Eur Urol; 2021 Mar; 79(3):e81-e82. PubMed ID: 33358233
[No Abstract] [Full Text] [Related]
3. Re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032: Interpreting the Effect of Ipilimumab Following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer.
Ludmir EB; McCaw ZR; Wei LJ
Eur Urol; 2021 Jan; 79(1):e10-e11. PubMed ID: 33109378
[No Abstract] [Full Text] [Related]
4. Re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024.
de Bono J; Hussain M; Kang J
Eur Urol; 2021 Mar; 79(3):e83-e84. PubMed ID: 33358234
[No Abstract] [Full Text] [Related]
5. Re: Joaquin Mateo, Karim Fizazi, Silke Gillessen, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol 2019:75:285-93.
von Eyben FE; Bauman G
Eur Urol; 2020 Mar; 77(3):e67-e68. PubMed ID: 31300234
[No Abstract] [Full Text] [Related]
6. Re: Joaquin Mateo, Karim Fizazi, Silke Gillessen, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:285-93.
Rocco B; Sighinolfi MC
Eur Urol; 2020 Mar; 77(3):e69. PubMed ID: 31151677
[No Abstract] [Full Text] [Related]
7. Re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
Qi F; Xu Z; Zou Q
Eur Urol; 2023 Mar; 83(3):e76-e77. PubMed ID: 36604272
[No Abstract] [Full Text] [Related]
8. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA; Chen AH; Parikh K
Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
[TBL] [Abstract][Full Text] [Related]
9. Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer.
McHenry MB; Drake CG; Fizazi K
Eur Urol; 2021 Jan; 79(1):e12-e13. PubMed ID: 33121826
[No Abstract] [Full Text] [Related]
10. Reply to Feng Qi, Zicheng Xu, and Qing Zou's Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
Loehr A; Chowdhury S; Abida W
Eur Urol; 2023 Mar; 83(3):e78. PubMed ID: 36623951
[No Abstract] [Full Text] [Related]
11. Stratifying prostate patients for olaparib.
Cancer Discov; 2015 Jun; 5(6):568-9. PubMed ID: 25904654
[TBL] [Abstract][Full Text] [Related]
12. Re: Olaparib for Metastatic Castration-resistant Prostate Cancer.
Di Lorenzo G; Autorino R
Eur Urol; 2020 Nov; 78(5):767-768. PubMed ID: 32624284
[No Abstract] [Full Text] [Related]
13. Re: Olaparib for Metastatic Castration-resistant Prostate Cancer.
Cumberbatch M; Condon B; Lawrentschuk N; Murphy DG
Eur Urol; 2021 Feb; 79(2):319-320. PubMed ID: 32980168
[No Abstract] [Full Text] [Related]
14. Re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035: Corticosteroid-associated Adverse Events in Elderly Patients.
Roviello G; Bottini A; Generali D
Eur Urol; 2016 Aug; 70(2):e41. PubMed ID: 27181830
[No Abstract] [Full Text] [Related]
15. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
Marshall CH; Sokolova AO; McNatty AL; Cheng HH; Eisenberger MA; Bryce AH; Schweizer MT; Antonarakis ES
Eur Urol; 2019 Oct; 76(4):452-458. PubMed ID: 30797618
[TBL] [Abstract][Full Text] [Related]
16. Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in
Mateo J; de Bono JS; Fizazi K; Saad F; Shore N; Sandhu S; Chi KN; Agarwal N; Olmos D; Thiery-Vuillemin A; Özgüroğlu M; Mehra N; Matsubara N; Young Joung J; Padua C; Korbenfeld E; Kang J; Marshall H; Lai Z; Barnicle A; Poehlein C; Lukashchuk N; Hussain M
J Clin Oncol; 2024 Feb; 42(5):571-583. PubMed ID: 37963304
[TBL] [Abstract][Full Text] [Related]
17. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
[TBL] [Abstract][Full Text] [Related]
18. Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer.
Wallis CJD; Klaassen Z; Jackson WC; Dess RT; Reichert ZR; Sun Y; Spratt DE
JAMA Netw Open; 2021 May; 4(5):e2110950. PubMed ID: 34028551
[TBL] [Abstract][Full Text] [Related]
19. Olaparib Targets Some Advanced Prostate Cancers.
Cancer Discov; 2016 Jan; 6(1):OF1. PubMed ID: 26658963
[TBL] [Abstract][Full Text] [Related]
20. Reply to Giandomenico Roviello, Alberto Bottini, and Daniele Generali's Letter to the Editor re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035. Corticosteroid-associated Adverse Events in Elderly Patients.
Fizazi K; De Porre P; Londhe A; McGowan T; Ryan CJ
Eur Urol; 2016 Aug; 70(2):e42. PubMed ID: 27209539
[No Abstract] [Full Text] [Related]
[Next] [New Search]
